Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qianhai Health HoldingsHKSE:00911 +14.29%39 Gross Margin % is 2.81% as of Dec. 2025, which is 41% below its 10-year median of 4.73. GuruFocus rates HKSE:00911 with a GF Score™ of 39/100 and a GF Value™ of HK$0.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 939 Drug Manufacturers companies, Qianhai Health Holdings ranks worse than 97.76% on this metric.
Qianhai Health Holdings (HKSE:00911) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Qianhai Health Holdings had a gross margin of 2.81% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Qianhai Health Holdings Gross Margin % Related Terms
Qianhai Health Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Qianhai Health Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qianhai Health Holdings Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Qianhai Health Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Qianhai Health Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Qianhai Health Holdings (HKSE:00911) has a Gross Margin % of 2.81% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Qianhai Health Holdings and its competitors. This is 41% below median its historical median of 4.73. According to the industry distribution chart, Qianhai Health Holdings ranks #918 out of 939 companies in the Drug Manufacturers industry, placing it in the top 97.8%.
Is Qianhai Health Holdings' Gross Margin % too high?
Qianhai Health Holdings' current Gross Margin % of 2.81% is 41% below median its 10-year median of 4.73. The Drug Manufacturers industry median Gross Margin % is 48.28. Qianhai Health Holdings' value of 2.81% is 94.2% below this industry median. Based on the distribution chart, Qianhai Health Holdings ranks #918 out of 939 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Qianhai Health Holdings has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qianhai Health Holdings' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Qianhai Health Holdings ranks #918 out of 939 companies for Gross Margin %. This places Qianhai Health Holdings in the lower half of its industry. The industry median Gross Margin % is 48.28. Qianhai Health Holdings' value of 2.81% is 94.2% below this benchmark. While the company's 10-year median is 4.73 vs. the industry median of 48.28, Qianhai Health Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.28, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qianhai Health Holdings's current Gross Margin % of 2.81% is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Qianhai Health Holdings and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qianhai Health Holdings's current Gross Margin % is 2.81%, which is 41% below median its own 10-year median of 4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qianhai Health Holdings stock overvalued right now?
Based on GuruFocus' analysis, Qianhai Health Holdings (HKSE:00911) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.22, compared to a current price of HK$0.60 — trading 172.7% above its estimated fair value. The current Gross Margin % is 2.81%, which is 41% below median its 10-year median of 4.73 and 94.2% below the Drug Manufacturers industry median of 48.28. Qianhai Health Holdings' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Qianhai Health Holdings (HKSE:00911), the current Gross Margin % is 2.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qianhai Health Holdings (HKSE:00911) Overvalued in 2026?
Based on GuruFocus' analysis, Qianhai Health Holdings stock appears to be overvalued.
The current stock price of HK$0.60 is trading 172.7% above its estimated GF Value™ of HK$0.22.
GuruFocus considers Qianhai Health Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00911:
Gross Margin %: 2.81% (41% below median its 10-year median of 4.73)
GF Value™: HK$0.22 vs. price of HK$0.60 (172.7% above fair value)
Industry Position: 94.2% below the Drug Manufacturers median (#918 of 939)
No single metric tells the full story. See the HKSE:00911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qianhai Health Holdings Ltd principally engaged in the sale of health products and electronic component products. It includes Chinese herbal medicines, skin-care and other healthcare products, and the sale of information technology components. The operating segments of the group are Healthcare products and Electronic component products. Healthcare products include the sale of healthcare products, including Chinese herbal medicines, skincare, and other healthcare products. Electronic component products include the sale of information technology components products including central processing units and semiconductors. The group's revenue is all derived from Hong Kong.
39GF Score
Get the complete analysis for HKSE:00911
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00911 has been successfully added to your 
